Product image of Melfalan Pliva (Melphalan Hydrochloride) supplied by GNH India

Melfalan Pliva

Active Ingredient:
Melphalan Hydrochloride
Origin:
EU

Melfalan Pliva (Melphalan Hydrochloride)

Melphalan hydrochloride, the active ingredient in Melfalan Pliva, is an alkylating agent presented as a sterile intravenous solution for infusion use. It is employed in the treatment of certain hematologic malignancies and solid tumors, including multiple myeloma, ovarian cancer and melanoma, by targeting rapidly dividing cancer cells.

GNH India supplies Melfalan Pliva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution, ensuring timely delivery.

Manufacturer / TM Owner

Pliva Hrvatska D.O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Melfalan Pliva (melphalan hydrochloride) is an alkylating chemotherapy used in the management of certain hematologic and solid tumor cancers.

  • Multiple Myeloma: Reduces disease progression and improves survival in eligible patients.
  • Ovarian Cancer: Enhances response rates when combined with other chemotherapeutic agents.
  • Melanoma: Provides therapeutic benefit in advanced-stage disease.
  • Other Solid Tumors: Used as part of combination regimens for various refractory solid malignancies.

How It Works

  • Melphalan hydrochloride exerts its antineoplastic effect by alkylating the N7 position of guanine bases in DNA, creating cross‑links that prevent DNA strand separation. This inhibition of DNA replication and transcription leads to cell cycle arrest and ultimately triggers apoptosis in rapidly proliferating cancer cells.

Side Effects

Melfalan Pliva may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Nausea and vomiting: Gastrointestinal upset commonly reported during treatment.
  • Myelosuppression: Decreased white blood cells, red cells, and platelets.
  • Alopecia: Temporary hair loss affecting scalp and body hair.
  • Fatigue: Generalized tiredness that may affect daily activities.

Serious or Rare Side Effects

  • Secondary malignancies: Potential development of new cancers after prolonged exposure.
  • Severe infection: Due to profound immunosuppression.
  • Pulmonary toxicity: Interstitial pneumonitis or fibrosis in rare cases.

Precautions & Warnings

Prior to initiating therapy, clinicians should assess patient-specific risk factors and monitor for toxicity.

  • Blood count monitoring: Perform complete blood counts regularly to detect myelosuppression.
  • Renal function assessment: Evaluate serum creatinine and adjust dosing if necessary.
  • Hepatic function assessment: Check liver enzymes before and during treatment.
  • Hypersensitivity avoidance: Discontinue if signs of allergic reaction appear.
  • Store at controlled room temperature: Keep in original container, protect from light and moisture.

Avoid Interactions

Melphalan may interact with other agents, requiring careful management.

Major Interactions (Avoid)

  • Concurrent myelosuppressive chemotherapy: Increases risk of severe bone marrow suppression.
  • High‑dose radiation therapy: Potentiates tissue toxicity.
  • Live viral vaccines: May cause uncontrolled infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

  • Anticoagulants: Enhanced bleeding risk; monitor coagulation parameters.
  • Nephrotoxic drugs: May exacerbate renal impairment; adjust dosing as needed.

Frequently Asked Questions

Melfalan Pliva contains melphalan hydrochloride, an alkylating chemotherapy indicated for the treatment of multiple myeloma, ovarian cancer, melanoma and selected solid tumors. It is administered intravenously as part of a prescribed oncology regimen.

Melphalan hydrochloride alkylates DNA by forming cross‑links at guanine residues, which blocks DNA replication and transcription. This disruption leads to cell cycle arrest and apoptosis, preferentially affecting rapidly dividing cancer cells.

The specific dose of Melfalan Pliva is determined by the treating oncologist based on the patient’s diagnosis, disease stage, body surface area and overall health. Dosing regimens are individualized and should follow the prescriber’s instructions.

Melphalan is classified as contraindicated in pregnancy because it can cause fetal harm. Women of childbearing potential should use effective contraception. Breastfeeding is not recommended while receiving melphalan, as the drug may be excreted in milk and affect the infant.

To request Melfalan Pliva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Melfalan Pliva (melphalan) is a nitrogen‑mustard alkylating agent with a well‑established role in multiple myeloma and certain solid tumors. Compared with cyclophosphamide, melphalan has a higher potency but a similar toxicity profile, requiring careful monitoring of blood counts and organ function.

Melfalan Pliva should be stored at controlled room temperature, below 25 °C, in its original packaging. Protect the product from light and moisture. Do not freeze. Follow aseptic techniques when preparing the intravenous solution.

Melfalan Pliva is given as an intravenous infusion. The preparation is diluted in an appropriate carrier solution and administered over a period defined by the prescribing oncologist, usually under close clinical supervision.

The most serious risks include severe myelosuppression leading to infection or bleeding, secondary malignancies, pulmonary toxicity, and organ dysfunction. Patients should be monitored closely for signs of infection, respiratory symptoms and laboratory abnormalities.

Melfalan Pliva is contraindicated in patients with known hypersensitivity to melphalan or other nitrogen‑mustard agents, in pregnant women, and in individuals with severe bone marrow failure or uncontrolled infections. Caution is advised for patients with significant renal or hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Melphalan Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT